Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia

Journal of the American Society of Nephrology

Volumn 20, Issue 7, 2009, Pages 1436-1443

  Singh, Ajay K ^a   Himmelfarb, Jonathan ^b   Szczech, Lynda Anne ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ANEMIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; HEART INFARCTION; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DOSE RESPONSE; HEMATOCRIT; KIDNEY DISEASE; METABOLISM; NOTE; RISK FACTOR;

ANEMIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; HEMATOCRIT; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; RISK FACTORS;

EID: 67649708228     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009040444     Document Type: Review

References (0)